GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 216.5

Change

0.00 (0.00)%

Market Cap

USD 13.44B

Volume

63.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

N/A

USD 492.09B
MATA:F Panasonic Corporation

N/A

USD 20.38B
1CK:F CK Asset Holdings Limited

N/A

USD 14.09B
0PY:F Paycom Soft

N/A

USD 8.78B
2U4:F HICL Infrastructure PLC

N/A

USD 2.89B
28MA:F CIELO SA SPONS. ADR 1

N/A

USD 2.57B
0LA:F ASSETMARK FIN. DL-001

N/A

USD 2.38B
CLN:F The City of London Investment ..

N/A

USD 2.04B
R7I:F RENEWABLES INFRASTRUCTURE

N/A

USD 1.77B
JR0:F Just Group plc

N/A

USD 1.77B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.67% N/A N/A 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.67% N/A N/A 23% F
Trailing 12 Months  
Capital Gain -35.98% N/A N/A 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.98% N/A N/A 20% F
Trailing 5 Years  
Capital Gain 16.30% N/A N/A 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.30% N/A N/A 55% F
Average Annual (5 Year Horizon)  
Capital Gain 7.31% N/A N/A 64% D
Dividend Return 7.31% N/A N/A 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.84% N/A N/A 45% F
Risk Adjusted Return 25.33% N/A N/A 52% F
Market Capitalization 13.44B N/A N/A 88% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike